recessive genetic disease caused by a deficiency of ␣-galactosidase A leading to accumulation of globotriaosylceramide (GL-3) in lysosomes of parenchymal and interstitial cells in multiple organs of the body, including skin, kidneys, and the cardiovascular system. 1 Cardiovascular manifestations in typical Fabry patients develop within the fourth decade and include left ventricular hypertrophy mimicking genetic hypertrophic cardiomyopathy (disorder of mutant contractile proteins) and accelerated coronary artery disease. 1 Cardiovascular manifestations also may develop in "cardiac variant" patients and symptomatic female heterozygotes, but later in life. 1 
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Recently, enzyme replacement therapy for Fabry disease has been introduced using intravenously administered recombinant ␣-galactosidase A (r-h␣GalA). [2] [3] [4] Initial evaluation in a Phase 3 trial focused on the histological clearance of GL-3 from the kidneys and skin on the basis of evaluation of renal and skin biopsies, respectively. 2, 3 In this issue of Circulation, Thurberg et al report a positive effect of r-h␣GalA therapy in terms of altering the vascular pathology in Fabry disease, using endomyocardial biopsy (EMB) coupled with light and electron microscopy as the evaluation method. 4 Pre-and posttreatment EMBs were analyzed from 58 Fabry patients enrolled in a 5-month, Phase 3, double-blind, randomized, placebo-controlled trial, followed by a 54-month open-label extension study of r-h␣GalA therapy. The r-h␣GalA was administered intravenously at 1 mg per kilogram of body weight every 2 weeks. EMBs were taken from the right ventricle from all 58 Fabry patients at baseline and 5 and 12 months after study initiation; 8 patients also had EMB at end-of-study month 60. Five months of treatment with r-h␣GalA resulted in complete clearance of GL-3 deposits from cells of the myocardial microvasculature in 72% of treated patients compared with only 3% of placebo patients (PϽ0.001). Similar results were achieved in the placebo group after 6 months of treatment in the open-label trial. Capillary endothelium remained free of GL-3 for up to 60 months in 6 of 8 patients who consented to an end-of-study EMB. However, no detectable clearance of GL-3 was observed in the cardiomyocytes. The authors concluded that long-term treatment with r-h␣GalA may halt the progression of vascular pathology and prevent the clinical manifestations of atherosclerotic disease in patients with Fabry disease.
Clearly, the development of genetically engineered r-h␣GalA and its therapeutic application, without significant complications, to retard the progression of pathology in patients with Fabry disease is a milestone in clinical translational medicine. The underlying rationale of the approach used by Thurberg and associates is that analysis of EMB can identify alterations in the myocardium and microvasculature that correlate with larger-vessel coronary artery disease and that comparison of serial EMBs can detect regression of microvascular pathological changes that are predictive of stabilization or regression of coronary artery disease. 4 Several aspects of this rationale and general approach to treatment of Fabry disease warrant consideration.
In the general population, coronary artery disease is usually due to coronary atherosclerosis. 5, 6 However, the spectrum of coronary arterial disease encompasses congenital and acquired conditions, atheromatous and nonatheromatous causes, and anatomic involvement that can include the major coronary arteries, epicardial coronary branches, and the intramyocardial microvasculature, with or without coexistent systemic vascular pathology. 7, 8 Involvement of the intramyocardial coronary vasculature typically is focused at the level of the small coronary arteries and arterioles in various conditions, including systemic hypertension, amyloidosis, diabetes mellitus, and certain forms of vasculitis. 7, 8 Functional abnormalities of the coronary microvasculature without a clear anatomic correlate have been implicated in coronary spasm and myocardial syndrome X. 9 Pathological evaluation can be helpful in determining the presence or absence of other causes of small-vessel disease in patients with a putative diagnosis of myocardial syndrome X. 10 Narrowing of myocardial capillaries by inclusion bodies (GL-3 storage deposits) in endothelial cells, as demonstrated by Thurberg et al in patients with Fabry disease, represents a very unusual and distinctive pattern of coronary arterial pathology. 4 Thurberg and associates proposed that the GL-3 accumulation in the microvasculature leads to endothelial injury and activation, leukocyte activation, and a coagulopathic state, abnormalities which also are components of atherosclerotic disease. 4 Thurberg et al point out that GL-3 is transported in low-density lipoprotein (LDL) and high-density lipoprotein particles, and vascular cells accumulate GL-3 from the circulation through the LDL receptor. 4 Furthermore, the vascular pathology in Fabry disease is referred to by Thurberg et al and other authors as accelerated atherosclerosis. However, published observations indicate that the vasculopathy of Fabry disease differs from classic atherosclerosis, a disease characterized by formation of atherosclerotic (atheromatous, "fibrous") plaques, which are lesions composed of various combinations of fibrous tissue and cholesterol-rich lipids. 5, 6 Involvement of large muscular arteries (coronary, renal, and intrarenal) in Fabry disease patients has been characterized by accumulation of GL-3 storage deposits in endothelium and smooth muscle cells of the media. [11] [12] [13] [14] [15] Progression of vasculopathy results in formation of a thickened fibrocellular intima containing fibroblasts with storage deposits and fibrosis and calcification of the media. [11] [12] [13] [14] [15] This form of vasculopathy has features of a type of fibromuscular dysplasia or a type of arteriosclerosis as literally defined rather than typical atherosclerosis of the elastic and muscular arteries. 5, 6 Although GL-3 uptake is via the LDL receptor, lipid accumulation in evolving atherosclerotic lesions involves local oxidation of LDL and poorly regulated cellular uptake of the oxidized LDL via scavenger pathway receptors, not the LDL receptor. 16 -18 Of course, individual patients may well be susceptible to secondary lipoprotein deposition in the evolving lesions. Progression of vasculopathy also may be complicated by a prothrombotic state. An interesting case report described occlusion of a left internal mammary artery graft while a saphenous vein bypass graft remained patent in a Fabry disease patient with coronary artery disease. 15 Factors promoting occlusion of the left internal mammary artery may have been the arterial pressure promoting GL-3 deposition as well as endothelial dysfunction favoring thrombosis. 15 The current report of Thurberg et al does not directly address the status of the pathophysiology or anatomy of the epicardial coronary arteries in this group of 58 patients with Fabry disease. 4 Also, the report is silent on the presence or absence of changes in myocardial vessels larger than capillaries, such as arterioles and small arteries, which may have been randomly sampled in the small EMBs. Thus, further correlative studies are needed to confirm whether the microvascular clearance of GL-3 deposits by r-h␣GalA therapy halts the progression of vascular pathology and prevents the clinical manifestations of macrovasculopathy, whether atherosclerotic, arteriosclerotic, or otherwise characterized, in patients with Fabry disease. With regard to methodology, the analysis was based on a semiquantitative scoring of histopathological findings by 3 independent pathologists who were blinded to the treatment information. Intraobserver and interobserver variability were not reported. Differences in grading were resolved by consensus. Although this approach has limitations, the figures demonstrating changes in degree of GL-3 deposits and the statistical analysis using the 2 method are convincing.
This report raises a broader consideration on the uses and indications for EMB. Historically, the EMB procedure was developed for evaluation of cardiac rejection in patients with cardiac transplantation. 19 Subsequently, EMB has been employed for a number of other uses and clinical indications. 19 A combined task force has recently published evidence-based guidelines for the clinical use of EMB. 20 The use of EMB has become embroiled in controversy relative to the diagnosis of myocarditis and cardiomyopathy. 21, 22 A dichotomy has arisen between the standard use of EMB as a diagnostic modality in major European centers and the currently less frequent use of EMB in the evaluation of patients with unexplained heart failure in North America. [23] [24] [25] [26] [27] Nevertheless, the literature supports the conclusion that the utility of EMB for the evaluation of myocarditis and unexplained heart failure can be increased when modern molecular techniques are combined with histopathological analysis.
In patients with cardiac transplantation, EMB has proven important for multiple indications. 28 EMB remains the gold standard for diagnosis and grading of acute cellular rejection. 28, 29 EMB also provides valuable information for the diagnosis of antibody-mediated (humoral) rejection. 28 However, evaluation of microvascular and other myocardial changes by EMB has been found to have limited sensitivity for the diagnosis of coronary vasculopathy in cardiac transplants with smoldering chronic rejection. 28 -30 An alternate approach based on measurement of molecular biomarkers from blood has been tested. 31 Information is scant on the use of EMB to detect microvascular changes or other markers that correlate with the progression of coronary atherosclerosis in the general population. Nevertheless, the report of Thurberg et al establishes the principle that EMB can be useful in monitoring the progression of microvascular changes that may correlate with progression of macrovasculopathy in certain groups of patients, including those with Fabry disease. 4 The report of Thurberg et al has other points of interest. 4 Complete microvascular clearance of GL-3 occurred in 72% (nϭ21) of patients by the semiquantitative criteria used in the study, but 28% of patients (nϭ8) had residual GL-3 endothelial deposits after 5 months of r-h␣GalA therapy. At the end of the 60 months, including the 54-month open-label period, the capillary endothelium remained free of GL-3 in 6 of 8 patients with end-of-study EMB. These results leave open the question of why a minority of patients did not exhibit microvascular clearance of GL-3. These results highlight the documented and poorly understood heterogeneity of disease severity in patients with Fabry disease, including differences between males with classic disease, those with the cardiac limited variant, and heterozygous females.
Another key finding is that the r-h␣GalA treatment protocol led to microvascular clearance of GL-3 deposits in many of the treated patients but did not result in significant clearance of GL-3 deposits from cardiomyocytes, on the basis of histological evaluation of EMB. Uncertainty remains, therefore, as to whether partial reduction of the mass of GL-3 deposits was present in cardiomyocytes such that continued r-h␣GalA therapy could lead to stabilization or regression of the increased left ventricular mass and related complications in patients with Fabry disease.
In summary, this intriguing report of an important clinical trial represents an excellent model of the blending of molec-ular biology, genetic engineering, and clinical translational medicine. EMB clearly had the major diagnostic and evaluative role in this study. Thus, the study of Thurberg et al provides a case in point on the successful application of EMB in the management of patients with certain forms of coronary artery disease.
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